Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.

Emily NguyenSam TrinhHuy TrinhHuy NguyenKhanh NguyenAivien DoBrian LevittSon DoMy NguyenTreta PurohitEugenie ShiehMindie H Nguyen

Published in: Alimentary pharmacology & therapeutics (2018)

Whether treatment-naïve, treatment-experienced, or cirrhotic patients with HCV GT 6 residing in the US had excellent outcomes when treated with SOF+VEL or LDV+SOF. Since LDV+SOF is more readily available globally, our results may provide clinicians with a treatment option when cost and availability limit the treatment choice.

Keyphrases

hepatitis c virus
type diabetes
adipose tissue
combination therapy
metabolic syndrome
human immunodeficiency virus
hiv infected
antiretroviral therapy
weight loss
replacement therapy